Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City, Cairo 11829, Egypt.
Pharmaceutical Chemistry Department, Faculty of Pharmacy, El Saleheya El Gadida University, Egypt.
Bioorg Chem. 2024 Nov;152:107727. doi: 10.1016/j.bioorg.2024.107727. Epub 2024 Aug 15.
Inflammation management presents a critical challenge in modern medicine, with nonsteroidal anti-inflammatory drugs (NSAIDs) being a widely used therapeutic option. However, their efficacy is often accompanied by significant gastrointestinal adverse effects, necessitating the exploration of safer alternatives, particularly through the investigation of cyclooxygenase-2 (COX-2) inhibitors. This study endeavors to address this imperative through the synthesis and evaluation of pyrazoline-phenoxyacetic acid derivatives. Among the synthesized compounds, 6a and 6c emerged as promising candidates, demonstrating potent COX-2 inhibition with IC values of 0.03 µM for both and selectivity index = 365.4 and 196.9, respectively. Furthermore, these compounds exhibited efficacy in mitigating formalin-induced edema in male Wistar rats, accompanied by favorable safety profiles upon histological examination of vital organs. Comprehensive safety assessments, including evaluation of creatinine, AST, and ALT enzymatic as well as troponin T and creatine kinase-MB levels, further reinforce the promising attributes of the synthetic candidates. Molecular docking studies endorsed by molecular dynamic simulations corroborate the biological findings, elucidating significant protein-ligand interactions at COX-2 active sites indicative of therapeutic potential.
炎症管理在现代医学中提出了一个关键的挑战,非甾体抗炎药(NSAIDs)是一种广泛使用的治疗选择。然而,它们的疗效往往伴随着显著的胃肠道不良反应,因此需要探索更安全的替代品,特别是通过研究环氧化酶-2(COX-2)抑制剂。本研究通过合成和评估吡唑啉-苯氧乙酸衍生物来解决这一需求。在所合成的化合物中,6a 和 6c 是有前途的候选物,对 COX-2 的抑制作用具有强大的活性,IC 值分别为 0.03µM 和 0.03µM,选择性指数分别为 365.4 和 196.9。此外,这些化合物在减轻雄性 Wistar 大鼠福尔马林诱导的水肿方面表现出疗效,并且在对重要器官进行组织学检查时显示出良好的安全性。全面的安全性评估,包括对肌酸酐、AST 和 ALT 酶以及肌钙蛋白 T 和肌酸激酶-MB 水平的评估,进一步增强了合成候选物的有前途的特性。分子对接研究通过分子动力学模拟得到支持,阐明了 COX-2 活性部位的重要蛋白-配体相互作用,表明具有治疗潜力。